Abuse deterrence focus of upcoming opioid formulations.
Lavine
Greg
G
D000701:Analgesics, Opioid / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry; D002626:Chemistry, Pharmaceutical / Q000379:methods; D006801:Humans; D009020:Morphine / Q000008:administration & dosage / Q000009:adverse effects / Q000737:chemistry; D009293:Opioid-Related Disorders / Q000517:prevention & control*; D010098:Oxycodone / Q000008:administration & dosage / Q000009:adverse effects / Q000737:chemistry; D010146:Pain / Q000188:drug therapy*; D013678:Technology, Pharmaceutical / Q000379:methods
D000701:Analgesics, Opioid; D009020:Morphine; D010098:Oxycodone